Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 186 results.
User Information
Export Records
  1. 1.   The Janus kinase 1 is critical for pancreatic cancer initiation and progression
  2. Shrestha, Hridaya; Rädler, Patrick D; Dennaoui, Rayane; Wicker, Madison N; Rajbhandari, Nirakar; Sun, Yunguang; Peck, Amy R; Vistisen, Kerry; Triplett, Aleata A; Beydoun, Rafic; Sterneck,Esta; Saur, Dieter; Rui, Hallgeir; Wagner, Kay-Uwe
  3. Cell Reports. 2024, May 10; 43(5): 114202.
  1. 2.   ARAF protein kinase activates RAS by antagonizing its binding to RASGAP NF1
  2. Su, Wenjing; Mukherjee, Radha; Yaeger, Rona; Son, Jieun; Xu, Jianing; Na, Na; Merna Timaul, Neilawattie; Hechtman, Jaclyn; Paroder, Viktoriya; Lin, Mika; Mattar, Marissa; Qiu, Juan; Chang, Qing; Zhao, Huiyong; Zhang, Jonathan; Little, Megan; Adachi, Yuta; Han, Sae-Won; Taylor, Barry S; Ebi, Hiromichi; Abdel-Wahab, Omar; de Stanchina, Elisa; Rudin, Charles M; Jänne, Pasi A; McCormick, Frank; Yao, Zhan; Rosen, Neal
  3. Molecular Cell. 2022, May 14;
  1. 3.   A molecular mechanism for the generation of ligand-dependent differential outputs by the epidermal growth factor receptor
  2. Huang, Yongjian; Ognjenovic,Jana; Karandur, Deepti; Miller, Kate; Merk,Alan; Subramaniam, Sriram; Kuriyan, John
  3. eLife. 2021, Nov 30; 10
  1. 4.   Potential of substituted quinazolines to interact with multiple targets in the treatment of cancer
  2. Choudhary, Shruti; Doshi, Arpit; Luckett-Chastain, Lerin; Ihnat, Michael; Hamel,Ernest; Mooberry, Susan L.; Gangjee, Aleem
  3. Bioogranic & Medicinal Chemistry. 2021, Apr 1; 35
  1. 5.   Delayed onset of inherited ALS by deletion of the BDNF receptor TrkB.T1 is non-cell autonomous
  2. Yanpallewar,Sudhirkumar; Fulgenzi, Gianluca; Tomassoni Ardori,Francesco; Barrick,Colleen; Tessarollo,Lino
  3. EXPERIMENTAL NEUROLOGY. 2021, Mar; 337
  1. 6.   New Therapeutic Opportunities for the Treatment of Squamous Cell Carcinomas: A Focus on Novel Driver Kinases
  2. Bensen, Ryan; Brognard,John
  3. International Journal of Molecular Sciences. 2021, Mar; 22(6):
  1. 7.   Oxygen Tension Regulates Lysosomal Activation and Receptor Tyrosine Kinase Degradation
  2. Hong,Jaewoo; Wuest, Todd R; Min,Yongfen; Lin,Charles
  3. Cancers. 2019, Nov; 11(11): pii: E1653..
  1. 8.   Review: Precision medicine and driver mutations: Computational methods, functional assays and conformational principles for interpreting cancer drivers
  2. Nussinov,Ruth; Jang,Hyunbum; Tsai,Chung-Jung; Cheng, Feixiong
  3. PLoS computational biology. 2019, Mar; 15(3):
  1. 9.   Design, Synthesis, and Biological Evaluation of 6-Substituted Thieno[3,2-d]pyrimidine Analogues as Dual Epidermal Growth Factor Receptor Kinase and Microtubule Inhibitors
  2. Romagnoli, Romeo; Prencipe, Filippo; Oliva, Paola; Baraldi, Stefania; Baraldi, Pier Giovanni; Schiaffino Ortega, Santiago; Chayah, Mariem; Kimatrai Salvador, Maria; Carlota Lopez-Cara, Luisa; Brancale, Andrea; Ferla, Salvatore; Hamel,Ernest; Ronca, Roberto; Bortolozzi, Roberta; Mariotto, Elena; Mattiuzzo, Elena; Viola, Giampietro
  3. JOURNAL OF MEDICINAL CHEMISTRY. 2019, Feb 14; 62(3): 1274-1290.
  1. 10.   Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR Inhibitor
  2. Helman, Elena; Nguyen, Minh; Karlovich, Chris; Despain, Darrin; Choquette, A Karin; Spira, Alexander I; Yu, Helena A; Camidge, D Ross; Harding, Thomas C; Lanman, Richard B; Simmons, Andrew D
  3. Clinical lung cancer. 2018, Nov; 19(6): 518-530.e7.
  1. 11.   Pregnancy on vandetanib in metastatic medullary thyroid carcinoma associated with multiple endocrine neoplasia type 2B
  2. Thomas, Nicholas; Glod, John; Derse-Anthony, Claudia; Baple, Emma L; Obsborne, Nigel; Sturley, Rachel; Vaidya, Bijay; Newbold, Kate; Brooke, Antonia
  3. Clinical endocrinology. 2018, May; (5): 754-756.
  1. 12.   Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib
  2. Kraft, Ira L.; Akshintala, Srivandana; Zhu, Yuelin; Lei, Haiyan; Derse-Anthony, Claudia; Dombi, Eva; Steinberg, Seth M.; Lodish, Maya; Waguespack, Steven G.; Kapustina, Oxana; Fox, Elizabeth; Balis, Frank M.; Merino, Maria J.; Meltzer, Paul S.; Glod, John W.; Shern, Jack F.; Widemann, Brigitte C.
  3. CLINICAL CANCER RESEARCH. 2018, Feb 15; 24(4): 753-765.
  1. 13.   KIT Suppresses BRAF(V600E)-Mutant Melanoma by Attenuating Oncogenic RAS/MAPK Signaling
  2. Neiswender, James V.; Kortum, Robert L.; Bourque, Caitlin; Kasheta, Melissa; Zon, Leonard I.; Morrison, Deborah; Ceol, Craig J.
  3. Cancer Research. 2017, Nov 01; 77(21): 5820-5830.
  1. 14.   Discovery and preclinical evaluation of 7-benzyl-N-(substituted)-pyrrolo [3,2-d]pyrimidin-4-amines as single agents with microtubule targeting effects along with triple -acting angiokinase inhibition as antitumor agents
  2. Pavana, Roheeth Kumar; Choudhary, Shruti; Bastian, Anja; Ihnat, Michael A.; Bai, Ruoli; Hamel, Ernest; Gangjee, Aleem
  3. BIOORGANIC & MEDICINAL CHEMISTRY. 2017, Jan 15; 25(2): 545-556.
  1. 15.   Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy
  2. Logue, J. S.; Morrison, D. K.
  3. Genes & Development. 2012, Apr; 26(7): 641-650.
  1. 16.   Tamalin Is a Critical Mediator of Electroconvulsive Shock-Induced Adult Neuroplasticity
  2. Yanpallewar, S. U.; Barrick, C. A.; Palko, M. E.; Fulgenzi, G.; Tessarollo, L.
  3. Journal of Neuroscience. 2012, Feb; 32(7): 2252-2262.
  1. 17.   Non-SH2/PDZ reverse signaling by ephrins
  2. Daar, I. O.
  3. Seminars in Cell & Developmental Biology. 2012, Feb; 23(1): 65-74.
  1. 18.   Vascular endothelial growth factor receptor 2 inhibition in-vivo affects tumor vasculature in a tumor type-dependent way and downregulates vascular endothelial growth factor receptor 2 protein without a prominent role for miR-296
  2. Langenkamp, E.; Zwiers, P. J.; Moorlag, H. E.; Leenders, W. P.; Croix, B. S.; Molema, G.
  3. Anti-Cancer Drugs. 2012, Feb; 23(2): 161-172.
  1. 19.   Eph/ephrin signaling in cell-cell and cell-substrate adhesion
  2. Singh, A.; Winterbottom, E.; Daar, I. O.
  3. Frontiers in Bioscience-Landmark. 2012, Jan; 17: 473-497.
  1. 20.   Population pharmacokinetic analysis of sorafenib in patients with solid tumours
  2. Jain, L.; Woo, S.; Gardner, E. R.; Dahut, W. L.; Kohn, E. C.; Kummar, S.; Mould, D. R.; Giaccone, G.; Yarchoan, R.; Venitz, J.; Figg, W. D.
  3. British Journal of Clinical Pharmacology. 2011, Aug; 72(2): 294-305.
  1. 21.   Association of Src-Related Kinase Lyn with the Interleukin-2 Receptor and Its Role in Maintaining Constitutive Phosphorylation of JAK/STAT in Human T-Cell Leukemia Virus Type 1-Transformed T Cells
  2. Shuh, M. S. M.; Morse, B. A.; Heidecker, G.; Derse, D.
  3. Journal of Virology. 2011, May; 85(9): 4623-4627.
  1. 22.   Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas
  2. Kummar, S.; Gutierrez, M. E.; Chen, A.; Turkbey, I. B.; Allen, D.; Horneffer, Y. R.; Juwara, L.; Cao, L.; Yu, Y. K.; Kim, Y. S.; Trepel, J.; Chen, H.; Choyke, P.; Melillo, G.; Murgo, A. J.; Collins, J.; Doroshow, J. H.
  3. European Journal of Cancer. 2011, May; 47(7): 997-1005.
  1. 23.   Peptide Structure Stabilization by Membrane Anchoring and its General Applicability to the Development of Potent Cell-Permeable Inhibitors
  2. Johannessen, L.; Remsberg, J.; Gaponenko, V.; Adams, K. M.; Barchi, J. J.; Tarasov, S. G.; Jiang, S.; Tarasova, N. I.
  3. Chembiochem. 2011, Apr; 12(6): 914-921.
  1. 24.   TLR-mediated signaling pathways circumvent the requirement for DAP12 in mast cells for the induction of inflammatory mediator release
  2. Smrz, D.; Iwaki, S.; McVicar, D. W.; Metcalfe, D. D.; Gilfillan, A. M.
  3. European Journal of Immunology. 2010, Dec; 40(12): 3557-3569.
  1. 25.   Epigenetic regulation of CpG promoter methylation in invasive prostate cancer cells
  2. Mathews, L. A.; Hurt, E. M.; Zhang, X. H.; Farrar, W. L.
  3. Molecular Cancer. 2010, Oct; 9: 17.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel